Browsing Tag
hypoparathyroidism
3 posts
What this Phase 1 milestone reveals about the next wave of GPCR-driven endocrine therapeutics
What does Septerna’s Phase 1 milestone mean for GPCR-driven endocrine innovation? Read how SEP-479 could reshape biotech strategy and market sentiment.
April 15, 2026
Ascendis Pharma bags YORVIPATH FDA approval for adult hypoparathyroidism
In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval to Ascendis Pharma A/S’s…
August 12, 2024
AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio
AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments…
March 15, 2024